[
    [
        {
            "time": "2021-08-04",
            "original_text": "迈瑞医疗：除了支持三级医院扩容之外，也在加强县级乃至基层医疗机构的疾病防控能力，三大业务领域都将因此不同程度受益",
            "features": {
                "keywords": [
                    "迈瑞医疗",
                    "三级医院",
                    "扩容",
                    "县级医疗机构",
                    "疾病防控",
                    "三大业务领域"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "迈瑞医疗：除了支持三级医院扩容之外，也在加强县级乃至基层医疗机构的疾病防控能力，三大业务领域都将因此不同程度受益",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-12-31",
            "original_text": "深企迈瑞医疗位居2020创新指数五百强第34位",
            "features": {
                "keywords": [
                    "迈瑞医疗",
                    "创新指数",
                    "五百强",
                    "第34位"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "深企迈瑞医疗位居2020创新指数五百强第34位",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-08-04",
            "original_text": "【兴证医药】新冠药物研发分析 - 医药行业周报(2021.08.02-2021.08.06)",
            "features": {
                "keywords": [
                    "兴证医药",
                    "新冠药物",
                    "研发分析",
                    "医药行业周报"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【兴证医药】新冠药物研发分析 - 医药行业周报(2021.08.02-2021.08.06)",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        }
    ]
]